Ventures

The Clinician-Founder’s Sequencing Problem: Evidence, Reimbursement and Distribution

Clinical insight is not a go-to-market strategy; clinician-founders need to stage proof, payment and access in the order their market actually requires.

The EditorsNovember 19, 20269 min read

Start With the Buyer’s Constraint, Not the Clinical Insight

Clinician-founders often begin with a legitimate observation: a workflow is broken, a diagnosis is missed, a complication is preventable, or a patient falls through a gap. That insight is valuable, but it is not yet a company. The first sequencing decision is to identify which constraint will actually block adoption: lack of clinical confidence, lack of payment, lack of budget ownership, lack of operational bandwidth, or lack of channel access. These constraints are not interchangeable. A hospital may agree that a tool improves care but still refuse to buy it if it creates uncompensated work, threatens service-line economics or requires scarce implementation resources.

The practical test is to map the product to a budget holder and a measurable economic event. Does the product help a provider capture existing reimbursement, avoid penalties, reduce labor cost, increase throughput, improve risk adjustment, retain patients, or shift care to a lower-cost setting? If the answer is only that it produces better medicine, the founder has identified a clinical rationale but not a purchasing rationale. In healthcare, the person who benefits clinically is often not the person who pays, and the person who pays is often not the person asked to change behavior.

This is where clinician-founders have both an advantage and a blind spot. They understand the care pathway, but they may overestimate how strongly clinical logic drives institutional decisions. The sequencing question should therefore be framed economically: what evidence would make the relevant buyer safer saying yes than saying no? For some products, that means peer-reviewed outcomes. For others, it means billing feasibility, integration cost, physician adoption data or proof that the product does not slow down the front line.

Evidence Should Be Built for the Decision It Must Unlock

Not all evidence has the same job. Early technical validation shows that a product can work. Clinical validation shows that it can change a patient-relevant measure. Economic validation shows that the change matters to a buyer or payer. Operational validation shows that the product can be used reliably in the real environment where care is delivered. Clinician-founders get into trouble when they build one type of evidence and expect it to answer all objections.

The right evidence sequence depends on the adoption pathway. If a product requires physician trust before use, early evidence must reduce professional skepticism: diagnostic accuracy, safety, reproducibility and comparison to standard practice. If the product requires executive budget approval, the evidence must quantify cost, utilization, capacity or revenue impact. If the product requires payer coverage, the evidence must connect the intervention to outcomes that payers recognize, within a time horizon they can underwrite. A beautiful pilot showing engagement or satisfaction may be irrelevant if the payer is asking whether admissions, drug spend or procedure volume changed.

The most efficient founders define an evidence ladder. The first rung may be retrospective data or a usability study. The second may be a prospective observational study in the target workflow. The third may be a pragmatic trial or multi-site deployment with economic endpoints. The key is that each rung should de-risk the next commercial decision. Evidence that is interesting but not decision-enabling consumes time, capital and goodwill. In medtech and digital health, weak sequencing is often disguised as scientific diligence.

Clinician-founders should also avoid treating publication as the only evidence currency. Peer review matters, especially for novel clinical claims, but buyers also rely on implementation references, coding analysis, actuarial models, service-line data and user-level adoption metrics. The evidence package should reflect the market. A chief medical officer, revenue cycle leader, self-insured employer and Medicare Advantage plan do not buy the same proof, even when they are looking at the same patient problem.

Reimbursement Is a Business Model Constraint, Not a Late-Stage Detail

Reimbursement strategy cannot be bolted on after product-market fit. Payment determines who can buy, how much they can pay, how often they can use the product and what evidence threshold applies. A device, diagnostic, software tool or service model may be clinically compelling but commercially constrained if it depends on codes that do not exist, coverage that is uncertain, or workflows that generate costs for one entity while savings accrue to another.

The first question is whether the company needs new reimbursement, can ride existing reimbursement, or can create value outside claims payment. Existing codes are attractive, but only if documentation, supervision, site-of-service and medical necessity rules fit the actual use case. New codes and coverage can support a durable market, but they require time, capital and evidence. Employer, provider or subscription models may avoid payer processes, but they still need a budget source and a reason to renew. Avoiding reimbursement does not avoid economics; it simply moves the burden to another buyer.

Clinician-founders should distinguish billing feasibility from payment predictability. It is one thing to identify a CPT code or DRG-related opportunity. It is another to know whether claims are paid consistently, what denial patterns look like, which payers require prior authorization, and whether adoption exposes customers to audit risk. A hospital revenue cycle team will see these issues quickly. If the founder cannot answer them, the product may be perceived as risky even if the clinical case is strong.

The reimbursement sequence should also account for evidence timing. Payers are conservative because they are being asked to fund use at scale. They generally want proof of net benefit in a defined population, not a broad assertion that earlier intervention is good. If the product relies on future coverage, the company needs a bridge strategy: narrow cash-pay segments, provider-funded deployments, risk-bearing partners, research-use revenue, or service lines with existing economics. Without that bridge, the company may run out of capital while waiting for the payment system to agree with the clinical logic.

Distribution Fails When Workflow Is Treated as a Training Issue

Distribution in healthcare is not only sales coverage. It is the ability to insert a product into a constrained clinical operation without breaking incentives, trust or throughput. Many clinician-founders underestimate this because they imagine adoption through the lens of the motivated early user. But scaled distribution depends on average users in average environments: understaffed clinics, overburdened nurses, skeptical physicians, fragmented IT teams and administrators balancing competing initiatives.

The mechanism of adoption is usually behavior change. Someone must order the test, place the device, click the alert, counsel the patient, interpret the result, document the encounter or follow up on the finding. Each step has a cost. If the product adds work before it creates value, the founder needs to know who absorbs that work and why. “Training” rarely solves a product that misallocates labor. Durable adoption usually comes from reducing a task, automating a handoff, fitting an existing visit, supporting an already measured metric, or making a financially relevant action easier.

Channel choice should follow workflow ownership. Selling to individual clinicians may work when the product is low-cost, self-contained and personally useful. Selling to health systems may be necessary when the product touches IT, compliance, credentialing or facility economics. Selling through payers may work when the intervention affects utilization and can be deployed across networks. Selling through device companies, distributors or EHR marketplaces can accelerate reach but usually compress margins and reduce control. The wrong channel creates false positives: interest without implementation.

Institutional distribution also has a time-cost that founders must price into the plan. Security review, contracting, legal terms, integration, clinical governance and budget cycles can take longer than the initial sales conversation. A pilot is not distribution if it depends on executive sponsorship, founder involvement and exceptional effort. The distribution milestone that matters is repeatable deployment: a second and third site using a playbook, not a bespoke rescue mission.

Sequence Narrowly Before Expanding the Claim

Clinician-founders are often tempted to define the market by the full clinical potential of the idea. That is understandable, but it can be commercially dangerous. Broad claims expand the evidence burden, confuse the buyer and dilute implementation focus. A narrower initial wedge is usually more effective: a specific patient population, site of care, workflow, payer segment or service-line problem where the product’s value can be demonstrated with fewer dependencies.

The best wedge is not always the largest clinical need. It is the segment where evidence, reimbursement and distribution align soonest. For example, a monitoring product may have broad relevance across chronic disease, but the first market might be a post-discharge population with high readmission risk and an accountable budget owner. A diagnostic may eventually support population screening, but the first market may be specialist triage where false positives and follow-up pathways are manageable. A surgical tool may improve outcomes generally, but the first buyer may care most about operating room time, implant utilization or complication rates in a defined procedure.

Narrow sequencing also improves capital efficiency. Investors do not need to see every possible use case validated at once. They need to see that the company can move from a specific pain point to a repeatable commercial motion. A focused claim lowers study complexity, shortens feedback loops and makes pricing easier to defend. It also makes failure more interpretable. If a narrow segment does not adopt despite aligned economics and usable evidence, the founder learns something real. If a broad market does not adopt, the cause may be impossible to diagnose.

Expansion should be earned, not assumed. Once a company proves adoption in one segment, it can extend the evidence base, pursue broader reimbursement, add integrations or enter adjacent channels. This staged approach may feel slower, but it reduces the probability of building a company around a generalized clinical thesis that no single buyer feels responsible for funding.

The Investable Plan Shows Which Risk Falls Next

For institutional investors, the strongest clinician-founder plans are not the ones with the most ambitious market maps. They are the ones that specify the order in which major risks will be retired. Clinical risk, regulatory risk, reimbursement risk, workflow risk and distribution risk should not sit in a vague backlog. They should be tied to milestones that change the company’s probability of success and justify the next tranche of capital.

A credible sequence might look like this: first, demonstrate that the product produces a reliable clinical signal in the target setting; second, show that the signal changes a decision or workflow; third, prove that the changed decision creates an economic outcome for a defined buyer; fourth, validate that payment or budget mechanics support repeat use; fifth, replicate deployment without founder-led heroics. The order will vary by category, but the discipline is the same. Each milestone should answer the next buyer objection, not merely create another slide.

Clinician-founders should be especially clear about what they are not proving yet. A company may not need randomized outcomes before its first commercial contract if the buyer is purchasing operational efficiency. Conversely, it may need rigorous comparative evidence before meaningful adoption if the product changes diagnosis or treatment. A company may not need a new reimbursement code if it improves capture of existing payment. Conversely, it may have no scalable model if coverage is speculative and no interim buyer has a reason to pay. Precision about these tradeoffs builds trust.

The core lesson is plain: clinical conviction is necessary but not sufficient. Evidence creates confidence, reimbursement creates economic permission, and distribution creates access to actual use. The founder’s job is to sequence these three so that each one unlocks the next. When they are pursued in the wrong order, companies accumulate pilots, abstracts and enthusiastic quotes without a market. When they are sequenced well, the company does not merely prove that care can be better; it proves who will adopt the improvement, why they will pay for it, and how it will spread.